pre-IPO PHARMA

COMPANY OVERVIEW

Torque is an immuno-oncology company developing Deep Primedâ„¢ cell therapies that direct and evoke immune responses in the tumor microenvironment. Torque's lead product candidate is Deep IL-15, which is in pre-IND development for hematologic and solid tumors.


LOCATION

  • Cambridge, MA, USA

  • THERAPEUTIC AREAS

  • Immunology
  • Oncology

  • WEBSITE

    https://www.torquetx.com/


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    flagship-pioneering


    PRESS RELEASES


    Nov 19, 2019

    Torque Presents Preclinical Data for Lead Deep-Primed Cellular Immunotherapy Programs at AACR 2019 Special Conference on Tumor Immunology and Immunotherapy


    Nov 8, 2019

    Torque Presents New Preclinical Data for Three Deep-Primed Cellular Immunotherapy Programs, Including Newly Unveiled Deep TLR, at SITC 2019 Meeting


    Jun 18, 2019

    FDA Grants Fast Track Designation for Torque's First Deep-Primed T Cell Cancer Immunotherapy Program, TRQ-1501


    Apr 1, 2019

    Torque Presents New Preclinical Data for its Deep-Primed Cellular Immunotherapy Programs at the American Association for Cancer Research (AACR) Annual Meeting


    Feb 20, 2019

    Torque Announces Clinical Trial Collaboration with Merck


    For More Press Releases


    Google Analytics Alternative